Galantamine Provides Sustained Benefits in Patients with ‘Advanced Moderate’ Alzheimer’s Disease for at Least 12 Months

Publisher： Karger

E-ISSN： 1421-9824|15|2|79-87

ISSN： 1420-8008

Source： Dementia and Geriatric Cognitive Disorders, Vol.15, Iss.2, 2003-01, pp. : 79-87

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Galantamine: Additional Benefits to Patients with Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 11, Iss. 1, 2000-09 ,pp. : 19-27

Karger

Access to resources Recommend Favorite

A 12-Month Study of the Efficacy of Rivastigmine in Patients with Advanced Moderate Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 19, Iss. 1, 2004-12 ,pp. : 51-56

Karger

Access to resources Recommend Favorite

Economic Analysis of Galantamine, a Cholinesterase Inhibitor, in the Treatment of Patients with Mild to Moderate Alzheimer’s Disease in The Netherlands

By  

Dementia and Geriatric Cognitive Disorders, Vol. 14, Iss. 2, 2002-07 ,pp. : 84-89

Karger

Access to resources Recommend Favorite

Galantamine Prolonged-Release Formulation in the Treatment of Mild to Moderate Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 20, Iss. 2-3, 2005-08 ,pp. : 120-132

Karger

Access to resources Recommend Favorite

Management of Patients with Alzheimer’s Disease plus Cerebrovascular Disease: 12-Month Treatment with Galantamine

By  

Dementia and Geriatric Cognitive Disorders, Vol. 17, Iss. 1-2, 2003-12 ,pp. : 29-34

Karger

Access to resources Recommend Favorite